Beyond Boundaries: Revolutionary CAR-T Therapies Pave Way To Conquer Solid Tumors

By Ayesha Pandit

As more clinical trials adopt chimeric antigen receptor (CAR) T-cell therapy for several cancer types, it's becoming a more significant component in cancer treatment. In just the past five years, CAR T-cell research in hematological malignancies has increased, as have investigations of this novel therapy in solid tumors, which comprise many cancers.

To date, the FDA has approved six CAR T-cell therapies, all for hematological malignancies and all primarily used as treatments for patients with advanced cancer who have exhausted other therapeutic options. Through historical observations of CAR-T cell therapy, its challenges, and the breakthroughs in clinical trials that have enabled its success in treating hematologic cancers, researchers can better understand the potential of CAR-T cell therapy to treat solid tumors.

Access the article for a comprehensive and insightful overview of the latest advancements in CAR-T cell therapy and their potential to transform oncology research.